The current severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) pandemic has resulted in a unique global challenge for health care delivery, both in terms of the clinical sequelae of viral infection (coronavirus disease-2019 \[COVID-19\]) and the unintended consequences related to over-taxed health care systems. The virus enters cells by binding to the angiotensin-converting enzyme-2 receptor, which is abundantly present in the lung, heart, and vascular endothelial cells ([@bib1]). This entry mechanism likely contributes to the clinical presentation of COVID-19 that includes pneumonia, hypoxemia, myocardial cell damage, cardiac dysfunction, and thrombosis, among others. The specific mechanism(s) of cardiac injury may include viral myocarditis, microthrombosis of small arterioles, cytokine-mediated plaque erosion or rupture, right-heart failure from acute respiratory distress syndrome, and oxygen supply-demand mismatch related to fever, tachycardia, and hypotension ([@bib1],[@bib2]). Elevation in serum troponin reflects cardiomyocyte injury (direct or indirect), which occurs in 12% to 28% of hospitalized COVID-19 patients and predicts a 5- to 10-fold increased risk of in-hospital death ([@bib3]). Thus, cardiac involvement in COVID-19 is both common and predictive of worse outcomes in affected patients.

In an effort to preserve resources, including personal protective equipment, hospital beds, and respiratory ventilators, the Centers for Disease Control and Prevention recommended deferral of elective cardiac procedures including coronary angiography and revascularization using either percutaneous coronary intervention (PCI) or coronary artery bypass grafting at the onset of the COVID-19 pandemic ([@bib4]). As hospitals filled with COVID-19 patients, fear grew among both care providers and the public regarding potential exposure to COVID-19, and many patients avoided going to hospitals or clinics ([@bib5]). Additionally, hospitals adopted extremely limited visitation policies, often excluding family members of patients who were undergoing urgent or emergency procedures or who were in critical condition, which worsened public perception of health care facilities as COVID-19 "hotspots." However, coincident with the rise in COVID-19 hospital admissions was an abrupt 30% to 40% decline in hospital visits for cardiovascular emergencies including STEMI, stroke, heart failure, and aortic dissection, in both Europe and the United States, despite the fact that patients with cardiovascular disease were at higher risk of complications related to COVID-19, including thrombotic events ([@bib6],[@bib7]). At a time when pandemic-related environmental and psychosocial stressors might have prompted an increased incidence of STEMI, this paradoxical decrease in STEMI presentation was associated with significant increases in out-of-hospital cardiac arrest and of death at home, compared to a similar time period in 2019, prior to the COVID-19 pandemic ([@bib8],[@bib9]). Furthermore, door-to-balloon and transfer in (door-to-door-to-balloon) STEMI times for primary PCI were also prolonged due to extensive safety precautions required to protect physicians and hospital staff and limit infectious exposure ([@bib10],[@bib11]). Concern over COVID-19 cardiac involvement "masquerading" as STEMI with ST-segment elevation in the absence of obstructive coronary disease in up to 50% of cases caused additional ambiguity in diagnosis for patients presenting with STEMI and created impediments to timely care delivery ([@bib12], [@bib13], [@bib14], [@bib15]). Even for those STEMI patients who presented for medical attention, the lack of accurate diagnostic COVID-19 testing coupled with concern by clinicians for infectious exposure prompted calls for thrombolytic therapy ("no touch approach") even in PCI-capable centers, despite established data that primary PCI reduced mortality associated with STEMI compared to thrombolytic therapy and current societal guidelines supporting primary PCI as the standard of care for STEMI ([@bib10],[@bib16]). Thus, both the delayed and the diminished presentations of STEMI have been associated with an increased incidence of out-of-hospital cardiac arrest and death at home, many of which were likely STEMIs occurring at home. Additionally, there appears to have been an increase in mechanical complications of late-presenting STEMI (ventricular septal defect, free wall rupture, papillary muscle rupture, left ventricular thrombus, congestive heart failure, and cardiogenic shock), as shown in the [Central Illustration](#undfig2){ref-type="fig"} ([@bib7],[@bib12], [@bib13]).Central IllustrationConsequences of Delayed Presentation of STEMISTEMI = ST-segment elevation myocardial infarction.

This issue of *JACC: Case Reports* focuses on the impact of delayed presentation of STEMI during the COVID era and the ensuing mechanical complications. Alsidawi et al. ([@bib17]) present cases of delayed STEMI presentation due to patient reluctance to seek medical attention that manifested as subacute coronary occlusions and concurrent ventricular septal defects. Albierto and Seresini et al. ([@bib18]) present a case of delayed anterolateral STEMI resulting in a ventricular free-wall rupture that required emergent surgical repair. Moroni et al. ([@bib19]) present a series of patients with delayed presentation for STEMI associated with cardiogenic shock on presentation. Kunkel and Anwaruddin ([@bib20]) describe a patient with delayed presentation of inferior STEMI that resulted in papillary muscle rupture and severe mitral regurgitation which required emergency surgical intervention. Yousefzai and Bhimaraj ([@bib21]) present a patient who was misdiagnosed with presumed COVID-19 infection but who actually had an acute coronary syndrome. Unfortunately, the delay in diagnosis had significant consequences.

Thus, COVID-19 has directly and indirectly impacted the care of patients with cardiovascular emergencies. Ambiguity in diagnosis, delay or lack of myocardial reperfusion, and regression from primary PCI as the treatment of choice for STEMI to thrombolysis despite current clinical practice guideline recommendations have taken STEMI care backward in time by decades ([@bib10]). Therefore, the Society for Cardiovascular Angiography and Interventions recently launched "The Seconds Still Count: Cardiovascular Disease Doesn't Stop for COVID-19" campaign ([@bib22]). We need strong support from current professional societal guidelines and a concerted public education campaign to bring the care of STEMI patients "Back to the Future."
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